Logo image of ARGX

ARGENX SE - ADR (ARGX) Stock Fundamental Analysis

NASDAQ:ARGX - Nasdaq - US04016X1019 - ADR - Currency: USD

595.19  +3.2 (+0.54%)

After market: 595.19 0 (0%)

Fundamental Rating

5

Overall ARGX gets a fundamental rating of 5 out of 10. We evaluated ARGX against 553 industry peers in the Biotechnology industry. ARGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARGX is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ARGX was profitable.
In the past year ARGX has reported a negative cash flow from operations.
In the past 5 years ARGX reported 4 times negative net income.
ARGX had a negative operating cash flow in each of the past 5 years.
ARGX Yearly Net Income VS EBIT VS OCF VS FCFARGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

ARGX has a Return On Assets of 13.42%. This is amongst the best in the industry. ARGX outperforms 95.84% of its industry peers.
ARGX has a Return On Equity of 15.14%. This is amongst the best in the industry. ARGX outperforms 95.30% of its industry peers.
Industry RankSector Rank
ROA 13.42%
ROE 15.14%
ROIC N/A
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ARGX Yearly ROA, ROE, ROICARGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30 -40

1.3 Margins

ARGX's Profit Margin of 38.01% is amongst the best of the industry. ARGX outperforms 98.01% of its industry peers.
Looking at the Gross Margin, with a value of 89.65%, ARGX belongs to the top of the industry, outperforming 92.41% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 38.01%
GM 89.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARGX Yearly Profit, Operating, Gross MarginsARGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

5

2. Health

2.1 Basic Checks

ARGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARGX has been increased compared to 1 year ago.
ARGX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ARGX has a worse debt to assets ratio.
ARGX Yearly Shares OutstandingARGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ARGX Yearly Total Debt VS Total AssetsARGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

An Altman-Z score of 31.89 indicates that ARGX is not in any danger for bankruptcy at the moment.
ARGX's Altman-Z score of 31.89 is amongst the best of the industry. ARGX outperforms 96.38% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.
ARGX's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. ARGX outperforms 43.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 31.89
ROIC/WACCN/A
WACC7.39%
ARGX Yearly LT Debt VS Equity VS FCFARGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

ARGX has a Current Ratio of 7.29. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
ARGX's Current ratio of 7.29 is fine compared to the rest of the industry. ARGX outperforms 66.91% of its industry peers.
A Quick Ratio of 6.68 indicates that ARGX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.68, ARGX is in the better half of the industry, outperforming 64.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.29
Quick Ratio 6.68
ARGX Yearly Current Assets VS Current LiabilitesARGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

8

3. Growth

3.1 Past

ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 194.52%, which is quite impressive.
Looking at the last year, ARGX shows a very strong growth in Revenue. The Revenue has grown by 31.82%.
Measured over the past years, ARGX shows a very strong growth in Revenue. The Revenue has been growing by 94.61% on average per year.
EPS 1Y (TTM)194.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%348.08%
Revenue 1Y (TTM)31.82%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.72%

3.2 Future

Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 104.18% on average per year.
ARGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.88% yearly.
EPS Next Y576.65%
EPS Next 2Y242.7%
EPS Next 3Y155.24%
EPS Next 5Y104.18%
Revenue Next Year64.81%
Revenue Next 2Y47.5%
Revenue Next 3Y39.17%
Revenue Next 5Y30.88%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARGX Yearly Revenue VS EstimatesARGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ARGX Yearly EPS VS EstimatesARGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 20 40 60 80

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

ARGX is valuated quite expensively with a Price/Earnings ratio of 103.69.
Compared to the rest of the industry, the Price/Earnings ratio of ARGX indicates a rather cheap valuation: ARGX is cheaper than 91.14% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.93, ARGX is valued quite expensively.
With a Price/Forward Earnings ratio of 27.30, ARGX can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, ARGX is valued cheaply inside the industry as 91.32% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ARGX to the average of the S&P500 Index (37.78), we can say ARGX is valued slightly cheaper.
Industry RankSector Rank
PE 103.69
Fwd PE 27.3
ARGX Price Earnings VS Forward Price EarningsARGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

ARGX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ARGX is cheaper than 90.05% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 28560.4
ARGX Per share dataARGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 155.24% in the coming years.
PEG (NY)0.18
PEG (5Y)N/A
EPS Next 2Y242.7%
EPS Next 3Y155.24%

More info and screens

0

5. Dividend

5.1 Amount

ARGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARGENX SE - ADR

NASDAQ:ARGX (7/28/2025, 8:08:19 PM)

After market: 595.19 0 (0%)

595.19

+3.2 (+0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)07-31 2025-07-31/bmo
Inst Owners39.98%
Inst Owner Change-0.26%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap36.43B
Analysts84.62
Price Target792.36 (33.13%)
Short Float %3.22%
Short Ratio4.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7909.56%
Min EPS beat(2)-38.07%
Max EPS beat(2)15857.2%
EPS beat(4)2
Avg EPS beat(4)3984.41%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)2003.12%
EPS beat(12)8
Avg EPS beat(12)1344.81%
EPS beat(16)12
Avg EPS beat(16)1027.8%
Revenue beat(2)2
Avg Revenue beat(2)6.37%
Min Revenue beat(2)5.75%
Max Revenue beat(2)6.99%
Revenue beat(4)3
Avg Revenue beat(4)5.41%
Min Revenue beat(4)-0.25%
Max Revenue beat(4)9.17%
Revenue beat(8)7
Avg Revenue beat(8)8.22%
Revenue beat(12)11
Avg Revenue beat(12)28.07%
Revenue beat(16)14
Avg Revenue beat(16)44.01%
PT rev (1m)1.18%
PT rev (3m)-1.94%
EPS NQ rev (1m)-2.22%
EPS NQ rev (3m)0.08%
EPS NY rev (1m)-0.23%
EPS NY rev (3m)-2.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.41%
Valuation
Industry RankSector Rank
PE 103.69
Fwd PE 27.3
P/S 16.63
P/FCF N/A
P/OCF N/A
P/B 6.62
P/tB 6.85
EV/EBITDA 28560.4
EPS(TTM)5.74
EY0.96%
EPS(NY)21.8
Fwd EY3.66%
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-1.35
OCFYN/A
SpS35.79
BVpS89.84
TBVpS86.88
PEG (NY)0.18
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.42%
ROE 15.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 38.01%
GM 89.65%
FCFM N/A
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 29.94
Cap/Depr 389.69%
Cap/Sales 3.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.29
Quick Ratio 6.68
Altman-Z 31.89
F-Score2
WACC7.39%
ROIC/WACCN/A
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)194.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%348.08%
EPS Next Y576.65%
EPS Next 2Y242.7%
EPS Next 3Y155.24%
EPS Next 5Y104.18%
Revenue 1Y (TTM)31.82%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.72%
Revenue Next Year64.81%
Revenue Next 2Y47.5%
Revenue Next 3Y39.17%
Revenue Next 5Y30.88%
EBIT growth 1Y97.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1034.03%
EBIT Next 3Y192.38%
EBIT Next 5Y122%
FCF growth 1Y67.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.31%
OCF growth 3YN/A
OCF growth 5YN/A